Safety and Effectiveness of Nintedanib in Korean Patients

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

January 13, 2021

Primary Completion Date

August 2, 2022

Study Completion Date

August 18, 2022

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Nintedanib

Nintedanib

Trial Locations (22)

10380

Inje University Ilsan Paik Hospital, Gyeonggi-do

13620

Seoul National University Bundang Hospital, Gyeonggi-do

28644

Chungbuk national University Hospital, Chungcheongbuk-do

31151

SoonChunHyang University Cheonan Hospital, Chungcheongnam-do

42601

Keimyung University Dongsan Hospital, Daegu

44033

Ulsan University Hospital, Ulsan

49201

Dong-A University Hospital, Busan

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

51472

Gyeongsang National University Changwon Hospital, Gyeongsangnam-do

54538

Wonkwang Univertisy Hospital, Jeollabuk-do

54907

Jeonbuk National University Hospital, Jeollabuk-do

61469

Chonnam National University Hospital, Gwangju

63241

Jeju National University Hospital, Jeju-do

67924

Myongji Hospital, Gyeonggi-do

02447

KyungHee University Medical Center, Seoul

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

04763

Hanyang University Medical Center, Seoul

05278

Kyung Hee University Hospital at Gangdong, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

06591

Catholic University of Korea Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT04525547 - Safety and Effectiveness of Nintedanib in Korean Patients | Biotech Hunter | Biotech Hunter